Journal
LUNG CANCER
Volume 111, Issue -, Pages 65-68Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.lungcan.2017.07.012
Keywords
NSCLC; Adenocarcinoma; EGFR; Small cell lung cancer; Transformation; Nivolumab
Categories
Funding
- NHS
Ask authors/readers for more resources
Small cell transformation is a rare but well recognised mechanism of acquired resistance to EGFR-TKI therapy in EGFR-mutated NSCLC, but optimal drug therapy thereof is unknown. Nivolumab has demonstrated activity in relapsed de novo small cell lung cancer in early phase trials. Here, we report a case of transformed EGFR-mutant SCLC treated with nivolumab with no benefit.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available